Phase 0 Exploratory Study of [18F]MNI-1020 (Also Known as [18F]JNJ-64326067) as an Imaging Marker for Tau Protein in the Brain of Subjects With Alzheimer's Disease Compared to Healthy Subjects

Trial Profile

Phase 0 Exploratory Study of [18F]MNI-1020 (Also Known as [18F]JNJ-64326067) as an Imaging Marker for Tau Protein in the Brain of Subjects With Alzheimer's Disease Compared to Healthy Subjects

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Fluorine-18-MNI-1020 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker; Diagnostic use; Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 31 Oct 2017 Last checked against ClinicalTrials.gov record.
    • 25 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 01 Sep 2017 Planned End Date changed from 6 Nov 2017 to 20 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top